IIP
BIO icon

Intermede Investment Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Intermede Investment Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-226,803
Closed -$171M – 30
2021
Q4 		$171M Buy
226,803
+6,625
+3% +$4.96M 3.53% 13
2021
Q3 		$164M Buy
220,178
+33,204
+18% +$24.9M 3.78% 12
2021
Q2 		$120M Buy
186,974
+50,600
+37% +$30.8M 2.74% 21
2021
Q1 		$77.9M Sell
136,374
-88,439
-39% -$52.4M 1.99% 24
2020
Q4 		$131M Buy
224,813
+43,641
+24% +$24.9M 3.79% 16
2020
Q3 		$93.4M Buy
181,172
+4,691
+3% +$2.38M 3.9% 13
2020
Q2 		$79.7M Sell
176,481
-40,057
-18% -$17.7M 3.9% 17
2020
Q1 		$75.9M Sell
216,538
-3,663
-2% -$1.35M 4.47% 13
2019
Q4 		$81.5M Buy
220,201
+25,391
+13% +$8.95M 4.12% 17
2019
Q3 		$64.8M Buy
194,810
+53,569
+38% +$17.5M 3.6% 17
2019
Q2 		$44.2M Buy
141,241
+25,066
+22% +$7.51M 2.61% 21
2019
Q1 		$35.5M Buy
116,175
+34,779
+43% +$9.39M 2.21% 22
2018
Q4 		$18.9M Buy
+81,396
New +$21.8M 1.51% 26

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Intermede Investment Partners's BIO Position: Q1 2022 in Review

Intermede Investment Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 226,803 shares — an estimated $171M sold.

Intermede Investment Partners first reported a position in BIO in Q4 2018 and held it in 13 quarters. The position peaked at $171M in Q4 2021. 514 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

  • Intermede Investment Partners reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
  • Intermede Investment Partners sold 226,803 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $171M.
  • Intermede Investment Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 13 quarters.
  • Intermede Investment Partners's Bio-Rad Laboratories Class A position peaked at $171M in Q4 2021.
  • 514 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Intermede Investment Partners's 13F filing for Q1 2022, filed 28 Apr 2022.